Avalyn Pharma (NASDAQ:AVLN) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Avalyn Pharma from “sell” to “hold,” while analyst sentiment overall remains a “Moderate Buy” with an average price target of $60.00.
• AVLN opened at $33.57, with a 52-week range of $24.15 to $40.17 and a market capitalization of approximately $1.49 billion.
• Avalyn reported a quarterly loss of $0.98 per share, beating the consensus estimate of a $1.03 loss, while several hedge funds—including Montanova Capital and Braidwell—recently acquired positions.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

AVLN has been the topic of a number of other research reports. Weiss Ratings started coverage on Avalyn Pharma in a report on Thursday, August 13th. They issued a "sell (d+)" rating on the stock. Zacks Research raised Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Jefferies Financial Group began coverage on Avalyn Pharma in a research note on Monday, May 25th. They set a "buy" rating and a $52.00 price objective on the stock. Guggenheim began coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They set a "buy" rating and a $80.00 price objective on the stock. Finally, Evercore started coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They issued an "outperform" rating and a $51.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Avalyn Pharma presently has a consensus rating of "Moderate Buy" and an average target price of $60.00.

Avalyn Pharma Price Performance

AVLN opened at $33.57 on Friday. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $40.17. The firm has a market cap of $1.49 billion and a price-to-earnings ratio of -1.47. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $32.79.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $0.05. As a group, analysts expect that Avalyn Pharma will post -3.81 EPS for the current year.

Institutional Trading of Avalyn Pharma

Hedge funds have recently bought and sold shares of the business. Montanova Capital LLC bought a new stake in Avalyn Pharma in the second quarter worth about $82,402,000. Braidwell LP purchased a new position in Avalyn Pharma in the second quarter valued at about $26,382,000. Bank of New York Mellon Corp bought a new position in shares of Avalyn Pharma during the 2nd quarter valued at approximately $1,321,000. Finally, California State Teachers Retirement System bought a new position in shares of Avalyn Pharma during the 2nd quarter valued at approximately $236,000.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.